ID: ALA3973097

Max Phase: Preclinical

Molecular Formula: C21H17F2N5O2

Molecular Weight: 409.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(c1nccc2[nH]cnc12)N1CCC(F)(F)[C@@H](Oc2ccc3ccccc3n2)C1

Standard InChI:  InChI=1S/C21H17F2N5O2/c22-21(23)8-10-28(20(29)19-18-15(7-9-24-19)25-12-26-18)11-16(21)30-17-6-5-13-3-1-2-4-14(13)27-17/h1-7,9,12,16H,8,10-11H2,(H,25,26)/t16-/m0/s1

Standard InChI Key:  FEAVKDCRHLEQNS-INIZCTEOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 409.40

Molecular Weight (Monoisotopic): 409.1350

AlogP: 3.43

#Rotatable Bonds: 3

Polar Surface Area: 84.00

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.88

CX Basic pKa: 3.34

CX LogP: 2.98

CX LogD: 2.98

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.56

Np Likeness Score: -0.92

References

1. Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, McDonald TP, O'Brien J, Renger JJ, Williams PD, Winrow CJ, Coleman PJ..  (2016)  Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.,  26  (23): [PMID:27818110] [10.1016/j.bmcl.2016.10.019]

2. Préville C,Bonaventure P,Koudriakova T,Lord B,Nepomuceno D,Rizzolio M,Mani N,Coe KJ,Ndifor A,Dugovic C,Dvorak CA,Coate H,Pippel DJ,Fitzgerald A,Allison B,Lovenberg TW,Carruthers NI,Shireman BT.  (2020)  Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793.,  11  (10): [PMID:33062185] [10.1021/acsmedchemlett.0c00085]

Source

Source(1):

• Scientific Literature